http://www.pharmexec.com/pharmexec/Europe+Features/Article/list/48283 The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2013-05-20T16:59:19Z http://www.pharmexec.com/pharmexec/Europe+Features/Strategic-Acquisition-A-CEOs-View/ArticleStandard/Article/detail/746465?contextCategoryId=48283&ref=25 Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm. 2011-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/746465null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Strategic-Outsourcing-mdash-The-Road-to-Cost-Effic/ArticleStandard/Article/detail/738300?contextCategoryId=48283&ref=25 Big Pharma has increasingly turned to strategic outsourcing models to realize their own enterprise-wide strategic goals. Small- and medium-sized companies need to follow suit. 2011-09-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362011/738300null HTML http://www.pharmexec.com/pharmexec/Europe+News/Pharma-Companies-Contravene-New-ABPI-Code/ArticleStandard/Article/detail/725780?contextCategoryId=48283&ref=25 Is it a coincidence that the ABPI has netted a whole shoal of conduct contraveners in the first month its amended Code of Practice became operational? 2011-06-05T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/725780null HTML http://www.pharmexec.com/pharmexec/Europe/Hungary-Fails-to-Fill-Patient-Information-Gap/ArticleStandard/Article/detail/725148?contextCategoryId=48283&ref=25 Hungary?s failure to advance EU legislation on information to patients is not the country?s fault, says Reflector. 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232011/725148null HTML http://www.pharmexec.com/pharmexec/Global/Seeing-Through-the-Transparency-Directive/ArticleStandard/Article/detail/719597?contextCategoryId=48283&ref=25 The EU is largely powerless when it comes to policies over pricing and reimbursement 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719597null XML http://www.pharmexec.com/pharmexec/Global+Report/Dallis-Formula-Fails-the-Efficacy-Test/ArticleStandard/Article/detail/716291?contextCategoryId=48283&ref=25 EU leadership on pharma policy leaves many wondering of the right man is at the helm 2011-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162011/716291null XML http://www.pharmexec.com/pharmexec/Europe+Features/Single-European-Patent-System-Dealt-EU-Blow/ArticleStandard/Article/detail/714451?contextCategoryId=48283&ref=25 Philippa Montgomerie outlines the implications of the Court of Justice of the European Union's recent patent litigation forum shopping. 2011-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142011/714451null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Connecting-Physicians-Strengthening-the-Oncology-N/ArticleStandard/Article/detail/708541?contextCategoryId=48283&ref=25 Changes in the field of oncology in the last twenty years have led to complex networks between physicians. Doug Kitson reports on how Cegedim's Physician Connect Oncology aims to optimize these. 2011-02-25T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092011/708541/018_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092011/708541null HTML http://www.pharmexec.com/pharmexec/Europe/FDA-Should-Improve-Rate-of-Foreign-Inspections/ArticleStandard/Article/detail/694649?contextCategoryId=48283&ref=25 November 6, 2010. 2010-11-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462010/694649null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Bridging-the-Digital-Skills-Gap/ArticleStandard/Article/detail/688503?contextCategoryId=48283&ref=25 The industry is crying out for pharma marketers skilled in the theory and practice of online communication. Training is the key, says June Dawson. 2010-09-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/392010/688503null HTML http://www.pharmexec.com/pharmexec/Europe/A-SWOT-Analysis-Of-The-Biosimilars-Market/ArticleStandard/Article/detail/687202?contextCategoryId=48283&ref=25 Anjan Selz offers a Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market. 2010-09-15T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687202/Biosimilars_thumbnail.gif http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687202null XML http://www.pharmexec.com/pharmexec/Europe/Recipes-for-Success-in-India-and-China/ArticleStandard/Article/detail/686018?contextCategoryId=48283&ref=25 Dr Frank Floether provides a no-nonsense guide to securing a successful alliance in Asia. 2010-09-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372010/686018null HTML http://www.pharmexec.com/pharmexec/Europe/EGA-Talks-Biosimilars/ArticleStandard/Article/detail/682557?contextCategoryId=48283&ref=25 The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars. 2010-08-10T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682557/thumbnail_thumbnail.gif http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682557null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Choosing-Your-General-Manager-for-China/ArticleStandard/Article/detail/681322?contextCategoryId=48283&ref=25 With substantial growth predicted in the life sciences industry, appointing the right General Manager (GM) in China has never been more important. But where should he or she come from? 2010-08-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322010/681322null HTML http://www.pharmexec.com/pharmexec/Europe+News/Convention-Targets-Counterfeiting/ArticleStandard/Article/detail/680093?contextCategoryId=48283&ref=25 July 23, 2010. 2010-07-23T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302010/680093null HTML http://www.pharmexec.com/pharmexec/Europe/Cut-Your-IT-Costs-WIth-Shared-Services/ArticleStandard/Article/detail/678399?contextCategoryId=48283&ref=25 Kamal Biswas outlines some techniques for the successful design and implementation of an IT shared services model in pharma. 2010-07-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282010/678399null HTML http://www.pharmexec.com/pharmexec/Strategy/Response-to-the-Fiscal-Crisis-The-Valuing-Conversa/ArticleStandard/Article/detail/678273?contextCategoryId=48283&ref=25 As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough? 2010-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282010/678273null HTML http://www.pharmexec.com/pharmexec/Europe/Are-Your-Drugs-Taking-Too-Long-to-Get-to-Market/ArticleStandard/Article/detail/677299?contextCategoryId=48283&ref=25 Richard Watts and Chris Hart highlight some of the issues companies need to tackle to speed up their drug development process. 2010-07-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272010/677299null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Fairness-Risk-Sharing-and-the-European-Price-Cuts/ArticleStandard/Article/detail/676558?contextCategoryId=48283&ref=25 As pharma companies protest decisions to cut drug prices in Greece, Spain and Germany, the question of fair play is brought in sharp focus. But, says Jacky Law, even-handedness in drug pricing works both ways. 2010-06-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272010/676558null HTML http://www.pharmexec.com/pharmexec/Europe/BIO-2010-Potemkin-Pavillions-and-the-Power-of-NICE/ArticleStandard/Article/detail/674144?contextCategoryId=48283&ref=25 June 14, 2010. 2010-06-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/252010/674144null HTML http://www.pharmexec.com/pharmexec/Europe/Can-Combating-the-Counterfeiters-Hurt-Pharma-Too/ArticleStandard/Article/detail/673266?contextCategoryId=48283&ref=25 The broadening of the EU debate on counterfeit medicines may actually have some negative effects on Big Pharma, argues Reflector. 2010-06-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242010/673266null HTML http://www.pharmexec.com/pharmexec/Europe/How-to-Start-Your-Social-Media-Strategy/ArticleStandard/Article/detail/671647?contextCategoryId=48283&ref=25 It is now the job of the pharma marketer to get people talking and to listen to what they are saying. Jody Ball offers advice on making that transition. 2010-05-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222010/671647null HTML http://www.pharmexec.com/pharmexec/Europe/The-Ageing-Society-ndash-How-Will-We-Pay-for-It/ArticleStandard/Article/detail/667551?contextCategoryId=48283&ref=25 An exclusive report for Pharm Exec Europe by IMS Health. 2010-04-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182010/667551null HTML http://www.pharmexec.com/pharmexec/Europe/The-Changing-Face-of-European-Regulatory-Affairs/ArticleStandard/Article/detail/663632?contextCategoryId=48283&ref=25 In 1995, pharmaceutical regulation in Europe underwent a dramatic change with the emergence of the European Medicines Agency. The agency's 15-year history has been eventful, with it having to adapt to a changing regulatory landscape and new expectations from those relying on it for guidance. 2010-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142010/663632null XML http://www.pharmexec.com/pharmexec/Europe+Features/Healthcare-Focus-Let-End-Users-Help-Design-Busines/ArticleStandard/Article/detail/662948?contextCategoryId=48283&ref=25 Harold Hambrose explains why applying user-centric design to healthcare business systems can save money and lives. 2010-03-26T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132010/662948null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Mentoring-the-Mavericks/ArticleStandard/Article/detail/660982?contextCategoryId=48283&ref=25 Having a 'maverick' in your company can lead to problems as well as breakthroughs and innovations. Judith Germain outlines the value of harnessing a brilliant but wayward talent. 2010-03-11T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112010/660982null HTML http://www.pharmexec.com/pharmexec/Europe/New-Insights-Into-Open-innovation/ArticleStandard/Article/detail/660965?contextCategoryId=48283&ref=25 Open innovation is sometimes chaotic and often difficult to measure, but getting it right can give firms a real edge now and in the future. 2010-03-11T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112010/660965null HTML http://www.pharmexec.com/pharmexec/Europe/The-Power-of-Successful-Negotiation/ArticleStandard/Article/detail/659015?contextCategoryId=48283&ref=25 A corporate focus on negotiation can help organizations reap substantial and measurable benefit, writes Alison Morris. 2010-02-26T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092010/659015null HTML http://www.pharmexec.com/pharmexec/Europe/Advancing-Drug-Discovery-With-Research-Informatics/ArticleStandard/Article/detail/659059?contextCategoryId=48283&ref=25 Anirban Ghosh and Siddharth Sawhney explain how research informatics tools can advance the speed and success of drug discovery research. 2010-02-26T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092010/659059null HTML http://www.pharmexec.com/pharmexec/Europe/The-Seven-Deadly-Sins-of-Marketing-Excellence/ArticleStandard/Article/detail/657777?contextCategoryId=48283&ref=25 Marketing excellence programmes are popular, important and frequently flawed, says Dr Brian D. Smith 2010-02-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082010/657777null HTML http://www.pharmexec.com/pharmexec/Europe/EU-Pricing-Dilemmas/ArticleStandard/Article/detail/656074?contextCategoryId=48283&ref=25 Although representing a huge market, the EU also presents problems that hamper profitability— particularly when it comes to differing price regulations across member states. 2010-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072010/656074null XML http://www.pharmexec.com/pharmexec/Europe/Recruiting-and-Retaining-RampD-Staff-in-a-Recessio/ArticleStandard/Article/detail/651610?contextCategoryId=48283&ref=25 Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations. 2010-01-13T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032010/651610null HTML http://www.pharmexec.com/pharmexec/Europe/Pharmas-New-Commercialization-Model/ArticleStandard/Article/detail/648932?contextCategoryId=48283&ref=25 Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition. 2009-12-17T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648932null HTML http://www.pharmexec.com/pharmexec/Europe+Features/2010-Products-and-Therapy-Areas-to-Watch/ArticleStandard/Article/detail/645698?contextCategoryId=48283&ref=25 Thomson Reuters' global pharma forecast for next year. 2009-12-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/645698/thomson2_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/645698null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Branding-the-Pharma-Merger/ArticleStandard/Article/detail/644363?contextCategoryId=48283&ref=25 David Sun of InterbrandHealth looks at global pharma branding trends for 2010 and beyond. 2009-11-30T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492009/644363null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Lobbyists-Use-Limp-Sandwiches-to-Shape-the-Pharmac/ArticleStandard/Article/detail/638251?contextCategoryId=48283&ref=25 Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal 2009-11-02T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452009/638251null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Cegedim-Talks-CRM/ArticleStandard/Article/detail/634941?contextCategoryId=48283&ref=25 Cegedim CEO Laurent Labrune talks to Pharm Exec Europe about how the company is maintaining its CRM lead in a rapidly changing industry. 2009-10-19T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/432009/634941/laurentlabrune_DSF0016_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/432009/634941null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Why-Use-a-Clinical-Data-Warehouse/ArticleStandard/Article/detail/630131?contextCategoryId=48283&ref=25 An increasing pressure to get products to market means more data must be handled within a shorter time span. But how? 2009-10-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402009/630131null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Cellectis-French-Biotech-Without-Tears/ArticleStandard/Article/detail/631223?contextCategoryId=48283&ref=25 Pharm Exec Europe speaks to Cellectis CEO André Choulika about the biotech company's ongoing success and the advantages of being based in France. 2009-10-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/631223null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Takeda-takes-on-Europe/ArticleStandard/Article/detail/626813?contextCategoryId=48283&ref=25 Takeda's Dr Erich Brunn tells Pharm Exec Europe why now is the right time for the Japanese giant to get really serious about Europe. 2009-09-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626813null HTML http://www.pharmexec.com/pharmexec/Europe+Features/A-New-Approach-to-Managing-Safety-Information-in-C/ArticleStandard/Article/detail/626961?contextCategoryId=48283&ref=25 Clinical trials are conducted to prove the efficacy and safety of drugs, so why, Michael Reynolds asks, is so much emphasis is still centred just on efficacy? 2009-09-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626961null HTML http://www.pharmexec.com/pharmexec/Europe+Features/What-does-the-multi-channel-enabled-pharma-company/ArticleStandard/Article/detail/627592?contextCategoryId=48283&ref=25 "If you don't like change, you are going to like irrelevance even less." Gen Eric Shinseki US Army (ret.) 2009-09-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/627592null HTML http://www.pharmexec.com/pharmexec/Europe+Features/What-pharma-can-learn-from-general-manufacturing-i/ArticleStandard/Article/detail/626802?contextCategoryId=48283&ref=25 While pharma is not synchronized with the boom and bust of the general economy, lessons from the business cycle facing manufacturers can enable the pharmaceutical industry to tackle the problems it faces, writes Chris Hart of McKinney Rogers. 2009-09-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626802null HTML http://www.pharmexec.com/pharmexec/Europe+Features/The-New-Hot-Topics-in-Supply-Chain-Management/ArticleStandard/Article/detail/623509?contextCategoryId=48283&ref=25 Times are changing in the pharmaceutical and life sciences sectors and their supply chains are having to adapt to a new set of challenges, says Kenneth Porter of specialist consultancy Total Logistics. 2009-09-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362009/623509null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Meeting-the-Physician-Spend-Management-Challenge/ArticleStandard/Article/detail/623510?contextCategoryId=48283&ref=25 Ravi Shankar asks how pharmaceutical firms can best organise the vast amounts of data needed to stay in compliance with issues such as physician spend management. 2009-09-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362009/623510null HTML http://www.pharmexec.com/pharmexec/Europe/The-power-of-medical-animation/ArticleStandard/Article/detail/621867?contextCategoryId=48283&ref=25 The mechanism of action (MOA) animation is becoming an increasingly popular way to convey important information about a drug, but pharma companies are being slow to realise its potential. Faiz Kermani reports. 2009-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621867null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Need-a-new-non-executive-director/ArticleStandard/Article/detail/621864?contextCategoryId=48283&ref=25 Nick Stephens, CEO of RSA, talks to Pharm Exec Europe about how his company's new register aims to widen the choice of — and choices open to — non-executive directors in the life sciences industry. 2009-08-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621864null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Patent-litigation-insurance-a-win-win-situation/ArticleStandard/Article/detail/621865?contextCategoryId=48283&ref=25 James Blick explains how patent litigation insurance has evolved into a valid — and potentially vital — option for pharmaceutical companies. 2009-08-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352009/621865null HTML http://www.pharmexec.com/pharmexec/Europe/Sweden-takes-the-reins/ArticleStandard/Article/detail/619739?contextCategoryId=48283&ref=25 The presence of a high-flying Obama administration insider at the upcoming Swedish life sciences summit is just one indication of the seriousness with which the country taking its EU presidency. 2009-08-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619739null HTML http://www.pharmexec.com/pharmexec/Europe/Integrating-EU-and-US-regulation/ArticleStandard/Article/detail/619610?contextCategoryId=48283&ref=25 Frost & Sullivan's recently released report — Drug Approval Process in Europe: An Outlook — advocates the integration of the EU and US drug approval processes. 2009-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619610/Findlay1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619610null HTML http://www.pharmexec.com/pharmexec/Europe/Profile-Erin-Gainer/ArticleStandard/Article/detail/619613?contextCategoryId=48283&ref=25 Pharm Exec Europe talks to Dr Erin Gainer, newly-appointed CEO of HRA Pharma, about socially conscious projects, emergency contraception and her peripatetic past in public health and academia. 2009-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619613null HTML http://www.pharmexec.com/pharmexec/Europe/Key-Account-Management-always-read-the-label/ArticleStandard/Article/detail/619399?contextCategoryId=48283&ref=25 Dr Brian D. Smith traces the origins of key account management and how it applies in pharmaceutical markets. 2009-08-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619399null HTML http://www.pharmexec.com/pharmexec/Europe/Recession-Proof-Companies-Part-2-Norgine/ArticleStandard/Article/detail/619403?contextCategoryId=48283&ref=25 With 22 consecutive years of European growth under its belt, Norgine is still going from strength to strength. CEO Peter Stein talks to Pharm Exec Europe about the secret of its success. 2009-08-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342009/619403null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Belgiums-statin-stalemate/ArticleStandard/Article/detail/616342?contextCategoryId=48283&ref=25 Reflector reports on how Belgium's best intentions have backfired on its generics manufacturers. 2009-08-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616342null HTML http://www.pharmexec.com/pharmexec/Europe/Recession-proof-companiesbr--Part-I-Galapagos/ArticleStandard/Article/detail/614388?contextCategoryId=48283&ref=25 Galapagos CEO Onno van de Stolpe talks to Pharm Exec Europe about his 10-year run at the head of the company, a highly successful tenure that shows no sign of slowing down. 2009-08-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/614388null HTML http://www.pharmexec.com/pharmexec/Europe/Why-pharma-should-embrace-multi-level-competition/ArticleStandard/Article/detail/614420?contextCategoryId=48283&ref=25 Increasingly, pharma companies are expanding from brand vs brand to battle at the franchise, portfolio and corporate levels. Stan Bernard explains how this multi-level competition approach can help your company gain competitive advantage. 2009-08-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/614420null HTML http://www.pharmexec.com/pharmexec/Europe/Does-Big-Pharma-still-exist/ArticleStandard/Article/detail/612921?contextCategoryId=48283&ref=25 Jacky Law sees Roche's recent departure from PhRMA and ABPI as clear evidence that the Big Pharma model is breaking up. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612921null HTML http://www.pharmexec.com/pharmexec/Europe/The-antitrust-report-a-legal-perspective/ArticleStandard/Article/detail/612917?contextCategoryId=48283&ref=25 John Cassels of the Competition and EU Regulatory Group at Field Fisher Waterhouse sees the threat of litigation receding in the light of the EC Competition Commission's final report on the pharma sector. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612917null HTML http://www.pharmexec.com/pharmexec/Europe/A-quick-guide-to-EUs-new-pharmacovigilance-package/ArticleStandard/Article/detail/612918?contextCategoryId=48283&ref=25 Deirde McCarthy explains how you can achieve a streamlined and harmonised approach to adopting the EU's new pharmacovigilance guidelines. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612918null HTML http://www.pharmexec.com/pharmexec/Europe/The-EC-antitrust-report-results-are-in-Time-to-pop/ArticleStandard/Article/detail/612916?contextCategoryId=48283&ref=25 The climax of the antitrust investigation instigated with all guns blazing by EC commissioner Neelie Kroes last year has been a whimper, not a bang. Reflector reports. 2009-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/612916null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Novartis-Why-we-cant-give-free-flu-vaccine-to-poor/ArticleStandard/Article/detail/610863?contextCategoryId=48283&ref=25 Novartis' 'Rethinking Influenza' meeting earlier this month was understandably hijacked by issues surrounding swine flu, one of the most pertinent being the free supply of vaccines to the world's poorest nations. So why, on this issue, is Novartis not playing ball? 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610863null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Nycomed-licensing-for-long-term-success/ArticleStandard/Article/detail/610864?contextCategoryId=48283&ref=25 Gerhard Symons asks Dr Carlos de Sousa, Vice President Licensing at Nycomed (Zurich) about the firm's in-licensing activities, and what differentiates it from its mid-tier and Big Pharma competitors. 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610864null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Keeping-up-with-KOLs/ArticleStandard/Article/detail/611030?contextCategoryId=48283&ref=25 Dr Brian D. Smith looks at the origins and future of key opinion leadership. 2009-07-21T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/611030null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Big-Pharma-isnt-dead-but-long-live-small-pharma/ArticleStandard/Article/detail/610857?contextCategoryId=48283&ref=25 As the major companies grapple with various crises from patent expirations to regulatory clampdowns, Reflector looks at how small pharma is coming into its own. 2009-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610857null HTML http://www.pharmexec.com/pharmexec/Europe/Knock-em-dead-with-your-website-press-centre/ArticleStandard/Article/detail/603135?contextCategoryId=48283&ref=25 Tired of getting your press releases ignored? Joe Dysart shows you how, by tailoring your communications activities to Web 2.0, to court the media in ways that'll make you stand out. 2009-06-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/603135null HTML http://www.pharmexec.com/pharmexec/Europe/Opportunities-in-Vietnam/ArticleStandard/Article/detail/602440?contextCategoryId=48283&ref=25 Jane Wan explains why 'the land of the ascending dragon' is one emerging pharma market that shouldn't be ignored. 2009-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/602440null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Pharm-Exec-Digest-Europe-Issue-archive/ArticleStandard/Article/detail/602412?contextCategoryId=48283&ref=25 2008?2010 2009-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/602412null HTML http://www.pharmexec.com/pharmexec/Europe+Features/Reading-the-risk-radar/ArticleStandard/Article/detail/601616?contextCategoryId=48283&ref=25 Following the publication of an Ernst & Young report highlighting the 10 biggest business risks facing life science companies, Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a 'risk radar' to your organisation. 2009-06-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232009/601616null HTML http://www.pharmexec.com/pharmexec/Europe+Features/GSK-Clinical-Trials-African-Style/ArticleStandard/Article/detail/600055?contextCategoryId=48283&ref=25 Neil Darwent and Roger Cooper of GSK Biologicals talk to Pharm Exec Europe about the company's new, state-of-the-art approach to clinical trials in Africa. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600055null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/Only-the-bad-times-are-good-for-pharma/ArticleStandard/Article/detail/600039?contextCategoryId=48283&ref=25 Jacky Law looks at why the pharma industry has to wait for a global pandemic to be seen in a good light. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600039null HTML http://www.pharmexec.com/pharmexec/Europe+Features/How-much-should-pharma-CEOs-get-paid/ArticleStandard/Article/detail/600056?contextCategoryId=48283&ref=25 US pharma CEO salaries are still dwarfing the earnings of their European counterparts, but, with the industry and the economy currently in crisis, Jacky Law asks how long this can continue. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600056null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/Belgian-innovation-truffles-or-waffle/ArticleStandard/Article/detail/600036?contextCategoryId=48283&ref=25 Gerhard Symons takes the Eurostar to Belgium to visit some of the leading biotechnology firms in the Bruges-Ghent-Leuven axis in the Flanders region, and unearths the origins of this fertile soil. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600036null HTML http://www.pharmexec.com/pharmexec/Europe+Features/What-business-can-learn-from-the-military/ArticleStandard/Article/detail/600053?contextCategoryId=48283&ref=25 Chris Hart of McKinney Rogers relates how the military's experience of leadership can hold lessons that benefit pharmaceutical CEOs today. Having seen service in Bosnia and Northern Ireland, he is now a UK Partner of global business performance consultancy McKinney Rogers. 2009-05-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/222009/600053null HTML